In addition to our efforts to further grow our approved brands and to acquire new commercial and late stage development products, Cumberland is also focused on identifying and nurturing earlier stage product candidates that have the potential to improve patient care.

Our majority-owned subsidiary, Cumberland Emerging Technologies (CET), is jointly owned by Cumberland Pharmaceuticals, Vanderbilt University and the Tennessee Technology Development Corporation.  CET is working with leading universities to bridge the development gap and progress biopharmaceutical technologies from the research laboratory to the commercial marketplace.  CET’s grant program helps researchers and organizations prepare proposals for development funding, primarily through federal and state programs.

Through CET, Cumberland is able to foster and incubate interesting product candidates so that we may identify potential commercial opportunities and determine if there is a good strategic fit for the company. Our ifetroban development program is an example of this successful partnership between Cumberland and CET.